stars 1 stars 2 stars 3

Ewopharma is the successor company to M.R. Leclerc & Co., founded in 1959. From the start, our focus has been on building bridges to the pharmaceutical markets of Central Eastern Europe. Much has changed in the region since 1959 – both economically and politically – and over this period we have gained an in-depth understanding of the markets and an esteemed standing there. While we started out purely as a marketing partner for pharmaceutical companies, we have since acquired and launched proprietary products. Our brand Revalid® – a product line for holistic hair care and hair loss treatment–was developed in 1992 in Switzerland. In 2011, we acquired Irish healthcare company Newport Pharmaceuticals Ltd. giving us full ownership of the antiviral drug Isoprinosine® in 2011.Overseen by our head office in Schaffhausen, Switzerland, we now channel our industry knowledge and experience into the successful placement of both Ewopharma and partner brands in our target markets. In 2004, we joined the RX-Alliance, a professional cooperation network of successful pharmaceutical companies active in selected European markets.

Ewopharma Questions

The Ewopharma annual revenue was $63.4 million in 2026.

Alain Staub is the Chairman of the Board and CEO of Ewopharma.

223 people are employed at Ewopharma.

Ewopharma is based in Schaffhausen, Canton of Schaffhausen.

The NAICS codes for Ewopharma are [32, 3254, 32541, 325].

The SIC codes for Ewopharma are [283, 28].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users